Tumor-on-a-chip model for advancement of anti-cancer nano drug delivery system

Chutong Tian, Shunzhe Zheng, Xinying Liu, Ken ichiro Kamei

Research output: Contribution to journalReview articlepeer-review


Despite explosive growth in the development of nano-drug delivery systems (NDDS) targeting tumors in the last few decades, clinical translation rates are low owing to the lack of efficient models for evaluating and predicting responses. Microfluidics-based tumor-on-a-chip (TOC) systems provide a promising approach to address these challenges. The integrated engineered platforms can recapitulate complex in vivo tumor features at a microscale level, such as the tumor microenvironment, three-dimensional tissue structure, and dynamic culture conditions, thus improving the correlation between results derived from preclinical and clinical trials in evaluating anticancer nanomedicines. The specific focus of this review is to describe recent advances in TOCs for the evaluation of nanomedicine, categorized into six sections based on the drug delivery process: circulation behavior after infusion, endothelial and matrix barriers, tumor uptake, therapeutic efficacy, safety, and resistance. We also discuss current issues and future directions for an end-use perspective of TOCs.

Original languageEnglish (US)
Article number338
JournalJournal of Nanobiotechnology
Issue number1
StatePublished - Dec 2022


  • Drug delivery process
  • Microfluidic device
  • Nanomedicines
  • Preclinical prediction
  • Tumor-on-a-Chip

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Molecular Medicine
  • Biomedical Engineering
  • Applied Microbiology and Biotechnology
  • Pharmaceutical Science


Dive into the research topics of 'Tumor-on-a-chip model for advancement of anti-cancer nano drug delivery system'. Together they form a unique fingerprint.

Cite this